The development of targeted therapy is a true multidisciplinary enterprise involving physician scientists from the fields of nuclear medicine, radiation therapy, diagnostic radiology, surgery, gynaecology, pathology and medical oncology/haematology. It also involves many preclinical scientists working with experimental animal models, immunochemistry, recombinant antibody technologies, radiochemistry, radiation physics and basic cell biology.
It is the ambition of the editors to enable deeper insights in the process of improving targeted therapy. We believe that the time now has come when targeted therapy can soon be added to standard oncology treatment regimens.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
"This book is devoted to understanding the biological aspects of targeted radiotherapy and discusses in depth the various targeting agents as well as the radiopharmaceuticals used in targeted therapy. ... Physicians, physicians in training, and physicists who use radionuclide targeted agents in the specialties of radiation oncology, medical oncology, and nuclear medicine are the intended audience. ... Overall this is a very informative book for physicians particularly interested in the biological aspects of targeted radiotherapy." (James G. Douglas, Doody's Review Service, November, 2009)